Last reviewed · How we verify
NCT04854785
Neuroinflammation in COVID-19 and Depression
trial testing [18F]FEPPA PET scan in Major Depressive Episode in 77 participants. Completed in 21 December 2023.
21 December 2023
Quick facts
| Lead sponsor | Centre for Addiction and Mental Health |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 77 |
| Start date | 14 June 2021 |
| Primary completion | 21 December 2023 |
| Estimated completion | 21 December 2023 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- [18F]FEPPA PET scan
- [11C]SL25.1188 PET scan
Conditions studied
- Major Depressive Episode — all drugs for Major Depressive Episode →
- Covid19 — all drugs for Covid19 →
Sponsor
Centre for Addiction and Mental Health — full company profile →
Who can join
Adults 18 to 80, any sex, with Major Depressive Episode or Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to use state of the art brain imaging technology to investigate neuroinflammation in participants with depression after the respiratory symptoms of coronavirus disease 2019 (COVID-19) have passed.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.
van der Geest KSM, Sandovici M, Nienhuis PH, Slart RHJA, et al · · 2022 · cited 21× · PMID 35733858 · DOI 10.3389/fmed.2022.902155
Verify or expand the search:
- PubMed search for NCT04854785
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Major Depressive Episode
Currently open trials in the same condition.
- NCT07111390 — Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD) · NA · recruiting
- NCT07269964 — At-Home tDCS as Maintenance Therapy · NA · recruiting
- NCT05973643 — Metabolomics During ElectroConvulsivoTherapy · NA · recruiting
- NCT04130958 — Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics · NA · recruiting
- NCT06086366 — Presynaptic Imaging in Major Depressive Episodes After COVID-19 · recruiting
Other Centre for Addiction and Mental Health trials
Trials by the same sponsor.
- NCT07211438 — Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression · Phase 2 · not yet recruiting
- NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
- NCT07228923 — Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Tre · NA · not yet recruiting
- NCT07105449 — THC Titration of High-Potency Cannabis Concentrates · NA · not yet recruiting
- NCT06928935 — Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04854785 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre for Addiction and Mental Health
- Last refreshed: 22 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04854785.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing